Conatus Pharmaceuticals (CNAT) Competitors

Conatus Pharmaceuticals (NASDAQ:CNAT) and Traws Pharma (NASDAQ:TRAW) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, earnings, risk, valuation, profitability, community ranking, media sentiment and analyst recommendations.

Does the media refer more to CNAT or TRAW?

In the previous week, Conatus Pharmaceuticals' average media sentiment score of 0.00 equaled Traws Pharma'saverage media sentiment score.

Company	Overall Sentiment
Conatus Pharmaceuticals	Neutral
Traws Pharma	Neutral

Does the MarketBeat Community believe in CNAT or TRAW?

Conatus Pharmaceuticals received 537 more outperform votes than Traws Pharma when rated by MarketBeat users.

Company	Underperform	Outperform
Conatus Pharmaceuticals	Outperform Votes 537 79.67%	Underperform Votes 137 20.33%
Traws Pharma	N/A	N/A

Which has better earnings and valuation, CNAT or TRAW?

Conatus Pharmaceuticals has higher revenue and earnings than Traws Pharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Conatus Pharmaceuticals	$21.72M	0.76	-$11.39M	N/A	N/A
Traws Pharma	$230K	61.17	-$18.95M	-$0.91	-0.74

Which has more risk & volatility, CNAT or TRAW?

Conatus Pharmaceuticals has a beta of 1.84, indicating that its share price is 84% more volatile than the S&P 500. Comparatively, Traws Pharma has a beta of 1.38, indicating that its share price is 38% more volatile than the S&P 500.

Do insiders & institutionals believe in CNAT or TRAW?

15.2% of Conatus Pharmaceuticals shares are held by institutional investors. Comparatively, 8.0% of Traws Pharma shares are held by institutional investors. 11.3% of Conatus Pharmaceuticals shares are held by insiders. Comparatively, 3.3% of Traws Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Is CNAT or TRAW more profitable?

Conatus Pharmaceuticals has a net margin of -52.42% compared to Traws Pharma's net margin of -8,384.07%. Conatus Pharmaceuticals' return on equity of -48.22% beat Traws Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Conatus Pharmaceuticals	-52.42%	-48.22%	-39.32%
Traws Pharma	-8,384.07%	-113.18%	-65.76%

Do analysts prefer CNAT or TRAW?

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Conatus Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	N/A
Traws Pharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	N/A

Summary

Conatus Pharmaceuticals beats Traws Pharma on 9 of the 11 factors compared between the two stocks.